Jeffrey A. Moscow, MD, is a part-time Senior Investigator in the Investigational Drug Branch, CTEP. He is Professor of Pediatrics, Department of Pediatric Hematology-Oncology, University of Kentucky, where he continues to actively manage his laboratory. His portfolio includes erlotinib, lapatanib, AMG 386, and ch14.18.
As a clinician with an active research laboratory program, Dr. Moscow has always looked for ways to translate basic science findings into the clinic. His clinical research activities have been focused on anti-cancer drug development. Dr. Moscow successfully brought a novel anti-cancer agent, AR-67, into clinical trials, including successfully obtaining an IND. He has chaired a Children’s Oncology Group phase II study adding bortezomib to chemotherapy for relapsed acute myeloid leukemia, and he is a co-leader of the Drug Discovery, Delivery and Translational Therapeutics Program of the NCI-designated Markey Cancer Center. He is PI of an R01 grant that has enlisted a multi-disciplinary team to investigate a novel mechanism of chemotherapy-induced cognitive dysfunction. His laboratory interests started with an exploration of the expression of solute and nutrient transporters in cancer and are now focused on targeting thiamine-dependent enzymes for cancer therapy.
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850